Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Status:
Not yet recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
This study will determine if FSD201 reduces the average daily 24-hour recall pain intensity
after 28 and 56 days of treatment in adults with chronic widespread musculoskeletal
nociplastic pain.